UBS disclosed a direct stake in Renalytix, but the notice gives no purchase cost, reason, or plan. It reports no change to UBS's operations or expected profits, so its outlook is unchanged.
The notice gives no purchase cost, reason for the purchase, or plan linking the stake to UBS's operations. It reports no change to UBS's services or expected profits, so UBS's business outlook remains unchanged.
Renalytix was notified that UBS acquired a 5.13% voting stake. The notice gives no reason for the purchase or reports any change to Renalytix's business, so its outlook is unchanged.
Follow UBS Group AG (UBS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for UBS